Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue

British Journal of Pharmacology

Volumn 166, Issue 2, 2012, Pages 602-616

  Del Lungo, Martina ^a   Melchiorre, Michele ^a   Guandalini, Luca ^a   Sartiani, Laura ^a   Mugelli, Alessandro ^a   Koncz, Istvan ^b   Szel, Tamas ^b   Varro, Andras ^b   Romanelli, Maria Novella ^a   Cerbai, Elisabetta ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

bradycardic agents; HCN channels; HCN isoforms selectivity; I f current; I h current; neuropathic pain

Indexed keywords

3 [3 [[2 (3,4 DIMETHOXYPHENYL)ETHYL]METHYLAMINO]CYCLOHEXYL] 7,8 DIMETHOXY 1,3,4,5 TETRAHYDROBENZO[D]AZEPIN 2 ONE; [4 [[2 (3,4 DIMETHOXYPHENYL)ETHYL]METHYLAMINO]BUT 2 ENYL] 7,8 DIMETHOXY 1,3 DIHYDROBENZO[D]AZEPIN 2 ONE; CYCLIC NUCLEOTIDE GATED CHANNEL; EC 18; EC 32; EC 4; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL 1; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL 2; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL 4; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL BLOCKING AGENT; ION TRANSPORT AFFECTING AGENT; MEL 57A; MEL 57B; N,N BIS [4 (7,8 DIMETHOXY 2 OXO 1,3 DIHYDROBENZO[D]AZEPIN 3 YL)BUT 2 ENYL] 2 (3,4 DIMETHOXYPHENYL)PROPANAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; DOG; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; EMBRYO; GUINEA PIG; HEART DEPOLARIZATION; HUMAN; HUMAN CELL; MALE; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURKINJE FIBER; SINUS NODE; SPINAL GANGLION;

ANIMALS; BENZAZEPINES; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; CYCLOHEXANES; DOGS; FEMALE; GANGLIA, SPINAL; GUINEA PIGS; HEK293 CELLS; HUMANS; MALE; MICE; MUSCLE CELLS; NEURONS; PATCH-CLAMP TECHNIQUES; PROTEIN ISOFORMS; PURKINJE FIBERS; SINOATRIAL NODE;

EID: 84859898546     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01782.x     Document Type: Article

References (42)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Baruscotti M, Bucchi A, Difrancesco D, (2005). Physiology and pharmacology of the cardiac pacemaker ('funny') current. Pharmacol Ther 107: 59-79. (Pubitemid 40800408)
3. Biel M, Wahl-Schott C, Michalakis S, Zong X, (2009). Hyperpolarization- activated cation channels: from genes to function. Physiol Rev 89: 847-885.
4. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al,. (2010). Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376: 886-894.
5. Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators Group (2003). Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107: 817-823. (Pubitemid 36241038)
6. Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D, (2006). Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol 572 (Pt 2): 335-346.
7. Ceconi C, Comini L, Suffredini S, Stillitano F, Bouly M, Cerbai E, et al,. (2011). Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol 300: H366-H373.
8. Cerbai E, Barbieri M, Mugelli A, (1994). Characterization of the hyperpolarization-activated current, I(f), in ventricular myocytes isolated from hypertensive rat. J Physiol 481 (Pt 1): 585-591.
9. Cerbai E, Pino R, Porciatti F, Sani G, Toscano M, Maccherini M, et al,. (1997). Characterization of the hyperpolarization-activated current, I(f), in ventricular myocytes from human failing heart. Circulation 95: 568-571. (Pubitemid 27063029)
10. Cerbai E, Sartiani L, DePaoli P, Pino R, Maccherini M, Bizzarri F, et al,. (2001). The properties of the pacemaker current I(F)in human ventricular myocytes are modulated by cardiac disease. J Mol Cell Cardiol 33: 441-448. (Pubitemid 32539001)
11. Cervetto L, Demontis GC, Gargini C, (2007). Cellular mechanisms underlying the pharmacological induction of phosphenes. Br J Pharmacol 150: 383-390. (Pubitemid 46280644)
12. Cheng L, Kinard K, Rajamani R, Sanguinetti MC, (2007). Molecular mapping of the binding site for a blocker of hyperpolarization-activated, cyclic nucleotide-modulated pacemaker channels. J Pharmacol Exp Ther 322: 931-939. (Pubitemid 47295784)
13. Demontis GC, Gargini C, Paoli TG, Cervetto L, (2009). Selective Hcn1 channels inhibition by ivabradine in mouse rod photoreceptors. Invest Ophthalmol Vis Sci 50: 1948-1955.
14. Descoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V, et al,. (2011). Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med 3: 266-278.
15. DiFrancesco D, (2010). The role of the funny current in pacemaker activity. Circ Res 106: 434-446.
16. Ferrari R, Cargnoni A, Ceconi C, (2006). Anti-ischaemic effect of ivabradine. Pharmacol Res 53: 435-439. (Pubitemid 43729048)
17. Frishman WH, Pepine CJ, Weiss RJ, Baiker WM, (1995). Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group. J Am Coll Cardiol 26: 305-312.
18. Gaborit N, Le Bouter S, Szuts V, Varro A, Escande D, Nattel S, et al,. (2007). Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol 582 (Pt 2): 675-693. (Pubitemid 47040552)
19. Gargini C, Demontis GC, Bisti S, Cervetto L, (1999). Effects of blocking the hyperpolarization-activated current (Ih) on the cat electroretinogram. Vision Res 39: 1767-1774. (Pubitemid 29130487)
20. Glasser SP, Michie DD, Thadani U, Baiker WM, (1997). Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Zatebradine investigators. Am J Cardiol 79: 1401-1405. (Pubitemid 27280477)
21. Han W, Bao W, Wang Z, Nattel S, (2002). Comparison of ion-channel subunit expression in canine cardiac Purkinje fibers and ventricular muscle. Circ Res 91: 790-797. (Pubitemid 35285076)
22. Herrmann S, Stieber J, Ludwig A, (2007). Pathophysiology of HCN channels. Pflugers Arch 454: 517-522. (Pubitemid 46872890)
23. Hisada T, Ordway RW, Kirber MT, Singer JJ, Walsh JV Jr, (1991). Hyperpolarization-activated cationic channels in smooth muscle cells are stretch sensitive. Pflugers Arch 417: 493-499.
24. Koncz I, Szél T, Jaeger K, Baczkõ I, Cerbai E, Romanelli MN, et al,. (2011a). Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutical targets. Curr Med Chem 18: 3662-3674.
25. Koncz I, Szél T, Bitay M, Cerbai E, Jaeger K, Fülöp F, et al,. (2011b). Electrophysiological effects of ivabradine in dog and human cardiac preparations: potential antiarrhythmic actions. Eur J Pharmacol 668: 419-426.
26. Lee DH, Chang L, Sorkin LS, Chaplan SR, (2005). Hyperpolarization- activated, cation-nonselective, cyclic nucleotide-modulated channel blockade alleviates mechanical allodynia and suppresses ectopic discharge in spinal nerve ligated rats. J Pain 6: 417-424. (Pubitemid 40922692)
27. Lin W, Laitko U, Juranka PF, Morris CE, (2007). Dual stretch responses of mHCN2 pacemaker channels: accelerated activation, accelerated deactivation. Biophys J 92: 1559-1572. (Pubitemid 46393467)
28. Materazzi S, Nassini R, Andrè E, Campi B, Amadesi S, Trevisani M, et al,. (2008). Cox-dependent fatty acid metabolites cause pain through activation of the irritant receptor TRPA1. Proc Natl Acad Sci U S A 105: 12045-12050.
29. Melchiorre M, Del Lungo M, Guandalini L, Martini E, Dei S, Manetti D, et al,. (2010). Design, synthesis, and preliminary biological evaluation of new isoform-selective f-current blockers. J Med Chem 53: 6773-6777.
30. Momin A, Cadiou H, Mason A, McNaughton PA, (2008). Role of the hyperpolarization-activated current Ih in somatosensory neurons. J Physiol 586 (Pt 24): 5911-5929.
31. Moosmang S, Stieber J, Zong X, Biel M, Hofmann F, Ludwig A, (2001). Cellular expression and functional characterization of four hyperpolarization- activated pacemaker channels in cardiac and neuronal tissues. Eur J Biochem 268: 1646-1652. (Pubitemid 32862698)
32. Pérez O, Gay P, Franqueza L, Carrõn R, Valenzuela C, Delpõn E, et al,. (1995). Electromechanical effects of zatebradine on isolated guinea pig cardiac preparations. J Cardiovasc Pharmacol 26: 46-54.
33. Robinson RB, Siegelbaum SA, (2003). Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol 65: 453-480. (Pubitemid 38249163)
34. Romanelli MN, Cerbai E, Dei S, Guandalini L, Martelli C, Martini E, et al,. (2005). Design, synthesis and preliminary biological evaluation of zatebradine analogues as potential blockers of the hyperpolarization-activated current. Bioorg Med Chem 13: 1211-1220. (Pubitemid 40164605)
35. Romanelli MN, Mugelli A, Cerbai E, Sartiani L, Del Lungo M, Melchiorre M, (2010). New isoform-selective HCN blockers. 2010, PCT/EP2010/059369.
36. Sartiani L, Stillitano F, Cerbai E, Mugelli A, (2009). Electrophysiologic changes in heart failure: focus on pacemaker channels. Can J Physiol Pharmacol 87: 84-90.
37. Satoh TO, Yamada M, (2002). Multiple inhibitory effects of zatebradine (UL-FS 49) on the electrophysiological properties of retinal rod photoreceptors. Pflugers Arch 443: 532-540. (Pubitemid 34185057)
38. Stieber J, Wieland K, Stockl G, Ludwig A, Hofmann F, (2006). Bradycardic and proarrhythmic properties of sinus node inhibitors. Mol Pharmacol 69: 1328-1337.
39. Suffredini S, Stillitano F, Comini L, Bouly M, Brogioni S, Ceconi C, et al,. (2012). Long term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression. Br J Pharmacol 165: 1457-1466.
40. Valenzuela C, Delpõn E, Franqueza L, Gay P, Pérez O, Tamargo J, et al,. (1996). Class III antiarrhythmic effects of zatebradine. Time-, state-, use-, and voltage-dependent block of hKv1.5 channels. Circulation 94: 562-570. (Pubitemid 26266146)
41. Wickenden AD, Maher MP, Chaplan SR, (2009). HCN pacemaker channels and pain: a drug discovery perspective. Curr Pharm Des 15: 2149-2168.
42. Xue T, Marban E, Li RA, (2003). Dominant-negative suppression of HCN1- and HCN2-encoded pacemaker currents by an engineered HCN1 construct: insights into structure-function relationships and multimerization. Circ Res 90: 1267-1273. (Pubitemid 34787408)